HopeStage
Back to all studies
CompletedNCT06041646

Repeated Igalmi and agitation in schizophrenia or bipolarity

About this title

Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder

Read the official source — NCT06041646
Medication studyAges 18–65United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
Little Rock and 1 more locationSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: October 2, 2023
Recruitment status
Completed
Enrollment listed in the registry
29
Sponsor
BioXcel Therapeutics Inc
Sponsor type
Biotech company
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT06041646
Official title
Show the full official title

Characterization of Tachyphylaxis, Tolerance, and Withdrawal After Discontinuation of Igalmi in Frequently Agitated Schizophrenic or Bipolar Patients After 7 Days of PRN Treatment

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Little Rock · Rogers

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is BioXcel Therapeutics Inc.

Did this study involve medication?

Yes. The study involved medication, including Sublingual film containing Igalmi.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies